Navigation Links
X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
Date:11/1/2010

WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.  The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services.  This grant provides X-BODY with the maximum allowable 50% reimbursement of X-BODY's qualified investment of ~$500,000 in this project.

X-BODY's therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells. There is no selective inhibitor of this targeted pathway on the market. Targeting tumor-initiating cells via this pathway alone or with combination therapy may prevent metastasis in the treatment of non-small cell lung cancer and other solid tumors.  Non-small cell lung cancer is a very common cancer with an 11-14% five-year survival rate and causes ~1.4 million yearly deaths globally.

X-BODY's pre-clinical candidates were discovered using X-BODY's proprietary platform, based on innovative screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.    

About X-BODY BioSciences.

X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA.   Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007.  Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of th
'/>"/>

SOURCE X-BODY BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
2. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
3. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
4. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Cell Biosciences to Acquire Convergent Bioscience
7. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
8. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
9. YM BioSciences reports fiscal year end 2010 operational and financial results
10. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... N.Y., Aug. 1, 2011 Nycomed US Inc. ("Nycomed US") ... and Chief Executive Officer and member of the Board for ... the closing of the acquisition of Nycomed A/S by Takeda ... Bailey to the newly created position of Chief Operating Officer, ...
... a biopharmaceutical company pioneering a novel class of ... an entirely new class of naturally occurring human ... of these naturally supercharged human proteins enable biologic ... cells. This new class of proteins is the ...
... in the body, then alarm bells start ringing. ... disease and type 2 diabetes, formerly called adult-onset diabetes. ... then they might be able to treat such diseases ... colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and the university in ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 2Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 3In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... replace lost teeth with titanium dental implants could be improved. ... at micro level but also at nano level, researchers at ... method that could shorten the healing time for patients. , ... conductivity of the implant allows us to affect the body,s ...
... new type of cell in the immune system. ... belongs to a family of T-cells that play a critical ... could ultimately lead to the development of novel drugs that ... It is also potentially significant for many other ...
... 2011 Numera, a leading provider of innovative ... entered into a strategic partnership with HealthTrio LLC. ... integrate objective, biometric information from dozens of consumer-preferred ... Health Record (PHR). This new functionality will be ...
Cached Biology News:Healing times for dental implants could be cut 2New cell type offers immunology hope 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 3